Literature DB >> 3896476

A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.

K C Micetich, D Barnes, L C Erickson.   

Abstract

Utilizing the DNA alkaline elution technique we have compared qualitatively and quantitatively the DNA lesions produced in L1210 cells after a 2 h exposure to the antitumor agents, cis-(diammino) (1,1-cyclobutanedicarboxylato)-platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (DDP). DNA-protein and DNA interstrand cross-links are formed in cells exposed to either CBDCA or DDP. However, in comparison to DDP peak levels of these lesions occur 6 to 12 h later in CBDCA treated cells. Cytotoxicity studies reveal that CBDCA is 45 times less potent than DDP to L1210 cells when compared on a molar basis. The decreased cytotoxicity of CBDCA and the 12 h delay in peak cross-linking when compared to DDP is interpreted as a decreased reactivity of the intact CBDCA towards the DNA. This decreased reactivity may be due in part to the presence of a stable bidentate dicarboxylate chelate ring structure of CBDCA resulting in a much slower rate of hydrolysis to the active form of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896476

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

Authors:  W DeNeve; F Valeriote; E Tapazoglou; C Everett; A Khatana; T Corbett
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 2.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

4.  Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines.

Authors:  Ismaeil Haririan; Mohammad Shafiee Alavidjeh; Mohammad Reza Khorramizadeh; Mehdi Shafiee Ardestani; Zohre Zarei Ghane; Hassan Namazi
Journal:  Int J Nanomedicine       Date:  2010-02-02

Review 5.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 6.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

7.  Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.

Authors:  P A Steerenberg; C P Vendrik; W H de Jong; G de Groot; A M Fichtinger-Schepman; A P Scheefhals; J H Schornagel
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures.

Authors:  F Doz; M E Berens; D V Dougherty; M L Rosenblum
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

9.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Authors:  A J Wagstaff; A Ward; P Benfield; R C Heel
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.